Biofeedback for Headaches
Ann Int Med 101:128-131, , 1985
Biofeedback & Relaxation in the Treatment of Migraine Headaches
JNNP 46:525-532, LaCroix,J.M.,et al, 1983
Conditioned Adaptation-Relaxation Reflex in Migraine Therapy
JAMA 242:2102-2104, Dalessio,D.J.,et al, 1979
Biofeedback Therapy for Migraine Headaches
Arch Gen Psychiatry 33:517-519, Turin,A.,et al, 1976
Migraine, hearing loss, and blurred vision in a young woman
Neurol 95:e2945-e2950, Sasikumar, S.,et al, 2020
Encephalopathy in a Large Cohort of British Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Patients
Stroke 50:283-290, Drazyk, A.M.,et al, 2019
Clinicopathologic Conference, MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke like episodes)
NEJM 376:1668-1678, CASE 13-2017, 2017
Transition to Adult Care for Children with Chronic Neurological Disorders
Ann Neurol 69:437-444, Camfiled, P. & Camfield, C., 2011
Presentation, Diagnosis, Pathophysiology, and Treatment of the Neurological Features of Sturge-Weber Syndrome
The Neurologist 17:179-184, Comi, A.M., 2011
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts & Leukoencephalopathy (CADASIL)
UpToDate (www.uptodate.com) Aug 21, Dichgans,M.,et al., 2007
Posterior Cerebral Artery Stroke
e medicine, Hill,M.D., 2005
Central Anticholinergic Syndrome on Therapeutic Doses of Cyproheptadine
Pediatrics 103:158-160, Watemberg,N.M.,et al, 1999
Alternating Hemiplegia of Childhood:A Study of 10 Pts & Results of Flunarizine Treatment
Neurol 43:36-41, Silver,K.&Andermann,F., 1993
Classical Migraine:Symptoms Between Visual Aura and Headache Onset
Lancet 340:355-356, Blau,J.N., 1992
Recurrent Prolonged Coma Due to Basilar Artery Migraine:A Case Report
Headache 31:75-81, Frequin,S.T.F.M.,et al, 1991
Cerebrovascular and Neurologic Disease Associated with Antiphospholipid Antibodies:48 Cases
Neurol 40:1181-1189, Levine,S.R.,et al, 1990
Neurological Disease Associated with Antiphospholipid Antibodies
Ann Neurol 25:221-227, Briley,D.P.,et al, 1989
Transient Global Amnesia:Clinical Characteristics & Prognosis
Neurol 37:733-737, Miller,J.W.,et al, 1987
Neurologic Disorders in Renal Failure (1st of Two Parts)
NEJM 294:143, Raskin,N.H.,et al, 1976
Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
JNNP 35:385, Patten,B.M.,et al, 1972
Genetic Causes of Cerebral Small Vessel Diseases, A Parctical Guide for Neurologists
Neurol 100:766-783, Manini,A.,&Pantoni,L., 2023
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Factors Associated with Risk of Recurrent Transient Global Amnesia
JAMA Neurol 77:1551-1558, Morris, K.A.,et al, 2020
Cyclic Vomiting Syndrome in Children
AJGH 2:doi:10.33552/AJGH.2020, Al-Ansari, N., 2020
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age with Epilepsy
JAMA Neurol 76:783-790, Kim, H.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Vestibular Migraine
BMJ 366:L4213, Li, V.,et al, 2019
Treatment Effects and Comorbid Diseases in 58 Patients with Visual Snow
Neurol 93:e398-e403, vanDongen, R.M.,et al, 2019
Acute Treatment of Migraine in Children and Adolescents
Neurol 93:487-499, Oskoui, M.,et al, 2019
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Acute Vestibular Migraine Treatment with Noninvasive Vagus Nerve Stimulation
Neurol 93:e1715-e1719, Beh, S.C. & Friedman, D.I., 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Abdominal Migraine
BMJ 360;k179, Angus-Leppan, H.,et al, 2018
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
Migraine
NEJM 377:553-561, Charles, A., 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017